<DOC>
	<DOC>NCT02561884</DOC>
	<brief_summary>To demonstrate the bioequivalence of a Olostar Tab versus two co-administered reference IMPs Olmetec and Crestor.</brief_summary>
	<brief_title>A Single-dose, Randomized, Two-period, Two-treatment, Two-sequence, Crossover Bioequivalence Study on a Olostar Tab Versus Two Co-administered Reference Products Olmesartan Medoxomil and Rosuvastatin Calcium in Healthy Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Rosuvastatin Calcium</mesh_term>
	<mesh_term>Olmesartan Medoxomil</mesh_term>
	<criteria>BMI ≥ 18.5 and ≤ 30.0 kg/m2. No clinically significant findings in a 12lead electrocardiogram (ECG) Age 1860 years at screening History of severe allergy or allergic reactions to the IMPs or related drugs History of serious clinical illness that can impact fate of drugs including major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>